Promoting angiogenesis—rather than blocking it—may represent a new strategy for killing tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hicklin, D.J. & Ellis, L.M. J. Clin. Oncol. 23, 1011–1027 (2005).
Noguera-Troise, I. et al. Nature 444, 1032–1037 (2006).
Ridgway, J. et al. Nature 444, 1083–1087 (2006).
Artavanis-Tsakonas, S., Rand, M.D. & Lake, R.J. Science 284, 770–776 (1999).
Shutter, J.R. et al. Genes Dev. 14, 1313–1318 (2000).
Gale, N.W. et al. Proc. Natl. Acad. Sci. USA 101, 15949–15954 (2004).
Krebs, L.T. et al. Genes Dev. 18, 2469–2473 (2004).
Duarte, A. et al. Genes Dev. 18, 2474–2478 (2004).
Lawson, N.D., Vogel, A.M. & Weinstein, B.M. Dev. Cell 3, 127–136 (2002).
Patel, N.S. et al. Cancer Res. 65, 8690–8697 (2005).
Hainaud, P. et al. Cancer Res. 66, 8501–8510 (2006).
Jain, R.K. Science 307, 58–62 (2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Hicklin, D. Promoting angiogenesis to a fault. Nat Biotechnol 25, 300–302 (2007). https://doi.org/10.1038/nbt0307-300
Issue Date:
DOI: https://doi.org/10.1038/nbt0307-300
This article is cited by
-
Chronic DLL4 blockade induces vascular neoplasms
Nature (2010)
-
VEGF-targeted therapy: mechanisms of anti-tumour activity
Nature Reviews Cancer (2008)
-
Drug Insight: antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies
Nature Clinical Practice Gastroenterology & Hepatology (2008)